Data supporting the positive decision demonstrated that patients treated with Alluzience for wrinkles had a rapid onset of effect starting from day one, with improvements lasting up to six months.1 Galderma
Galderma Launches CETAPHIL Line for Sensitive Skin and New DAYLONG Sun Protection Product in Switzerland
quality dermatology line for sensitive skin is now available in Swiss pharmacies and drugstores
DAYLONG, a market-leading sun protection brand, is expanded to include practical DAYLONG Sun to Go cream and stick SPF 50+
Galderma has expanded its consumer care portfolio in Switzerland, where the global dermatology company originated and is headquartered. The expansion offers consumers more options for their dermatology needs. The move includes the introduction of the dermatologist-recommended CETAPHIL line for sensitive skin, as well as the expansion of the DAYLONG brand for sun protection.
Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis
patients quality of life
1
The outcome of a post-hoc analysis of the phase 2b study published in the Journal of the European Academy of Dermatology and Venerology provides new possibilities for patients struggling with uncontrolled atopic dermatitis
Clinical trial subjects treated with nemolizumab demonstrated significant itch relief as early as 48 hours after treatment
that persisted throughout the duration of the study (up to week 16)
2
Subjects treated with nemolizumab reported significant sleep improvements as early as 72 hours after the first injection which were sustained, and improved further throughout the duration of the trial (up to week 16)
Galderma Continues Global Growth Ambition With Sculptra (injectable poly-L-lactic Acid) Re-launch in Europe
Updated protocol allows for faster and more convenient administration of
Sculptra
with the optional addition of lidocaine to increase patient comfort
Update is based on new data from physiochemical and clinical studies evaluating the safety and effectiveness of
Sculptra
Virtual event held with European healthcare professionals to mark re-launch provided additional education and support on new protocol
Galderma today announced a European re-launch of
Sculptra (injectable poly-L-lactic acid) a collagen stimulator with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients.
Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe
Thursday, March 4, 2021 1:52PM IST (8:22AM GMT)
Updated protocol allows for faster and more convenient administration of
Sculptra® with the optional addition of lidocaine to increase patient comfort
Update is based on new data from physiochemical and clinical studies evaluating the safety and effectiveness of
Sculptra®
Virtual event held with European healthcare professionals to mark re-launch provided additional education and support on new protocol
Galderma today announced a European re-launch of
Sculptra
® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients.